CanBas Co., Ltd. (JP:4575)
:4575
Want to see JP:4575 full AI Analyst Report?
Top Page
CanBas Co., Ltd.
(4575)
Select Model
Select Model
Rating:45Neutral
Price Target:
¥519.00
▼(-34.05% Downside)
Action:Reiterated
Date:05/20/26
Overall score is held back mainly by persistent losses and ongoing cash burn (financial performance) and a clear technical downtrend (price below key moving averages with negative MACD). The strengthened, debt-free balance sheet provides some support, but negative earnings and no dividend data limit valuation confidence.
Positive Factors
Debt-free balance sheet
Zero reported debt and materially higher equity reduce leverage risk and give the firm structural financial flexibility to fund R&D or absorb setbacks. Over a 2–6 month horizon this supports runway, credit access and partner confidence versus highly leveraged peers.
Negative Factors
Persistent operating losses
Consistent operating and net losses with negative gross profit show the company is still in a pre-commercial, cash-consuming phase. Over several months this limits internal financing capacity and increases reliance on external capital or partner deals to sustain operations.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
Zero reported debt and materially higher equity reduce leverage risk and give the firm structural financial flexibility to fund R&D or absorb setbacks. Over a 2–6 month horizon this supports runway, credit access and partner confidence versus highly leveraged peers.
Read all positive factors
CanBas Co., Ltd. (4575) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥10.96B
Dividend YieldN/A
Average Volume (3M)268.48K
Price to Earnings (P/E)―
Beta (1Y)1.05
Revenue GrowthN/A
EPS Growth24.17%
CountryJP
Employees11
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-61.17
Shares Outstanding19,713,655
10 Day Avg. Volume208,910
30 Day Avg. Volume268,476
Financial Highlights & Ratios
PEG Ratio1.96
Price to Book (P/B)7.69
Price to Sales (P/S)0.00
P/FCF Ratio-29.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
CanBas Co., Ltd. Business Overview & Revenue Model
Company Description
CanBas Co., Ltd. is a biopharmaceutical company in the clinical stage, dedicated to discovering and developing new therapies for cancer patients. Its main investigational compounds include CBP501, a calmodulin-modulating peptide aimed at treating ...
How the Company Makes Money
CanBas Co., Ltd. primarily generates revenue through pharmaceutical R&D-related monetization, including (1) licensing and out-licensing arrangements in which it grants partners rights to develop and/or commercialize its drug candidates or related ...
CanBas Co., Ltd. Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
62
Positive
Cash Flow
18
Very Negative
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 108.94M |
| Gross Profit | -820.00M | -984.00M | -671.00M | -608.00M | -322.00M |
| EBITDA | -1.16B | 53.65M | -1.28B | -848.65M | -522.28M |
| Net Income | -1.16B | -1.21B | -1.24B | -855.58M | -531.03M |
Balance Sheet | |||||
| Total Assets | 3.05B | 2.43B | 2.09B | 790.71M | 1.30B |
| Cash, Cash Equivalents and Short-Term Investments | 2.83B | 1.89B | 1.62B | 737.77M | 1.15B |
| Total Debt | 0.00 | 0.00 | 0.00 | 367.34M | 749.99M |
| Total Liabilities | 107.00M | 91.99M | 153.85M | 540.02M | 857.64M |
| Stockholders Equity | 2.94B | 2.34B | 1.93B | 250.69M | 437.97M |
Cash Flow | |||||
| Free Cash Flow | -771.45M | -1.28B | -1.40B | -719.81M | -688.57M |
| Operating Cash Flow | -771.45M | -1.28B | -1.40B | -719.81M | -688.57M |
| Investing Cash Flow | 122.00K | 0.00 | 0.00 | 182.00K | 0.00 |
| Financing Cash Flow | 1.75B | 1.54B | 2.27B | 282.75M | 728.80M |
CanBas Co., Ltd. Technical Analysis
Negative
787.00
Price Trends
668.92
Negative
750.87
Negative
864.74
Negative
Market Momentum
-35.01
Positive
34.81
Neutral
38.27
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4575, the sentiment is Negative. The current price of 787 is above the 20-day moving average (MA) of 596.05, above the 50-day MA of 668.92, and below the 200-day MA of 864.74, indicating a bearish trend. The MACD of -35.01 indicates Positive momentum. The RSI at 34.81 is Neutral, neither overbought nor oversold. The STOCH value of 38.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4575.
CanBas Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | ¥23.72B | -32.28 | ― | ― | -11.11% | -187.80% | |
45 Neutral | ¥10.96B | -9.13 | ― | ― | ― | 24.17% | |
45 Neutral | ¥17.93B | -9.59 | ― | ― | ― | 6.10% | |
43 Neutral | ¥35.24B | -10.48 | ― | ― | -87.41% | 43.60% | |
42 Neutral | ¥12.08B | -20.34 | ― | ― | -25.02% | -697.06% | |
42 Neutral | ¥8.34B | -8.15 | ― | ― | -62.06% | 7.56% |
* Healthcare Sector Average
JP:4575
CanBas Co., Ltd.
556.00
-413.00
-42.62%
JP:4593
Healios KK
261.00
-280.00
-51.76%
JP:4599
StemRIM Inc.
286.00
-69.00
-19.44%
JP:4978
ReproCELL Inc.
127.00
-65.00
-33.85%
JP:7774
Japan Tissue Engineering Co., Ltd.
584.00
-27.00
-4.42%
JP:7776
CellSeed Inc.
213.00
-302.00
-58.64%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.